Meeting
2022 ASCO Genitourinary Cancers Symposium
A single arm, phase I/II trial of neoadjuvant androgen deprivation, darolutamide, and ipatasertib in men with localized, high-risk prostate cancer.
Authors
David James VanderWeele
Northwestern Unis, Chicago, IL
David James VanderWeele , Sarah Elizabeth Fenton , Gregory Auffenberg , Borko Jovanovic , Maha H. A. Hussain
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Trials in Progress Poster Session
Session Title
Trials in Progress Poster Session A: Prostate Cancer
Track
Prostate Cancer - Advanced,Prostate Cancer - Localized
Sub Track
Therapeutics
Clinical Trial Registration Number
NCT04737109
Citation
J Clin Oncol 40, 2022 (suppl 6; abstr TPS286)
DOI
10.1200/JCO.2022.40.6_suppl.TPS286
Abstract #
TPS286
Poster Bd #
R5
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Genitourinary Cancers Symposium
A phase I trial of androgen deprivation, darolutamide, and ipatasertib in a safety cohort with castration-resistant prostate cancer (ADDITION).
First Author: Sarah Elizabeth Fenton
Poster
2024 ASCO Genitourinary Cancers Symposium
Neoadjuvant darolutamide plus androgen deprivation therapy for high-risk/very high-risk localized prostate cancer: A multicenter, open-labeled, single-arm phase II trial.
First Author: Junlong Zhuang
Poster
2024 ASCO Genitourinary Cancers Symposium
SWOG S2210: A phase II study of neoadjuvant carboplatin for localized, high-risk prostate cancer with germline BRCA1/2 mutations.
First Author: Heather H. Cheng
Poster
2024 ASCO Genitourinary Cancers Symposium
A phase 2 study of neoadjuvant PARP inhibition followed by radical prostatectomy (RP) in patients with unfavorable intermediate-risk or high-risk prostate cancer with BRCA1/2 gene alterations (NePtune).
First Author: Rana R. McKay